Profile of pacritinib and its potential in the treatment of hematologic disorders.
about
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyJAK2 activation by growth hormone and other cytokinesALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.A comprehensive review of pacritinib in myelofibrosis.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia.Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer.Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.
P2860
Q26749870-9BBC3C3C-4795-4ABD-BC58-2BCE161A4B1EQ27003058-F3B453AD-810D-44E0-852C-FCA69F140C0EQ33687080-7C204D37-4224-4AF1-83FD-1B2D3DC5A2BCQ38428692-576738B4-9723-434C-8B85-35109E2D1B2DQ38554422-254B61C6-E25E-4C86-95AA-B8F429AA6BCBQ38586421-CE49EC09-0037-44D4-9AE1-8D6C6F5012F3Q39170500-406D274E-6D8F-4F73-8747-D0AA6FB97C43Q46325508-E13D8B27-E0CB-4D81-AB6A-B87373BD2884Q47233779-E5C377C1-2BBB-42BE-96D2-169F721FD4C7Q51742255-8F4FD958-3D68-4F34-8508-BBCC07C3892DQ54959839-44F70B4F-7767-4C0B-9F6D-367F76C73EA7Q54978608-0BDCAB00-BCC8-4BF9-85A8-F32982F12017
P2860
Profile of pacritinib and its potential in the treatment of hematologic disorders.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Profile of pacritinib and its potential in the treatment of hematologic disorders.
@en
type
label
Profile of pacritinib and its potential in the treatment of hematologic disorders.
@en
prefLabel
Profile of pacritinib and its potential in the treatment of hematologic disorders.
@en
P2093
P2860
P356
P1476
Profile of pacritinib and its potential in the treatment of hematologic disorders.
@en
P2093
Eleftheria Hatzimichael
Evangelos Briasoulis
Evangelos Tsolas
P2860
P304
P356
10.2147/JBM.S51253
P577
2014-08-19T00:00:00Z